Poly(ADP-Ribose) Polymerase Inhibition Improves Erectile Function by Activation of Nitric Oxide/Cyclic Guanosine Monophosphate Pathway in Diabetic Rats

Journal of Sexual Medicine

Volumn 9, Issue 5, 2012, Pages 1319-1327

  Li, Wen Ji ^a   Peng, Yubing ^a   Zhou, Juan ^a   Li, Bao ^a   Wang, Hao ^a   Zhang, Jun ^a   Wang, Zhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Animal model; Diabetes; Endothelial dysfunction; Erectile dysfunction; Poly(ADP Ribose) polymerase

Indexed keywords

3 AMINOBENZAMIDE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN KINASE B; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS CAVERNOSUM; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; MALE; NERVE STIMULATION; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

EID: 84862799998     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2012.02666.x     Document Type: Article

References (46)

1. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005;96:257-80.
2. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU guidelines on erectile dysfunction: An update. Eur Urol 2006;49:806-15.
3. Tsujimura A, Yamanaka M, Takahashi T, Miura H, Nishimura K, Koga M, Iwasa A, Takeyama M, Matsumiya K, Takahara S, Okuyama A. The clinical studies of sildenafil for the ageing male. Int J Androl 2002;25:28-33.
4. Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002;14:466-71.
5. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
6. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003;92:19-25.
7. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: Role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol 2005;68:226-32.
8. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-20.
9. Bivalacqua TJ, Sussan TE, Gebska MA, Strong TD, Berkowitz DE, Biswal S, Burnett AL, Champion HC. Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J Urol 2009;181:899-906.
10. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: A randomized trial. Asian J Androl 2007;9:134-41.
11. Basu A, Ryder RE. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004;64:2667-88.
12. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009;6:1232-47.
13. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: Endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 2005;7:1568-80.
14. Kiss L, Szabo C. The pathogenesis of diabetic complications: The role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity. Mem Inst Oswaldo Cruz 2005;100(1 suppl):29-37.
15. Nangle MR, Cotter MA, Cameron NE. Poly(ADP-Ribose) polymerase inhibition reverses nitrergic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice. J Sex Med 2010;7:3396-403.
16. Wan ZH, Li WZ, Li YZ, Chen L, Li GH, Hu WF, Peng S, Yu JJ, Guo F. Poly(ADP-Ribose) polymerase inhibition improves erectile function in diabetic rats. J Sex Med 2011;8:1002-14.
17. Li WJ, Zhou J, Li B, Wang H, Peng YB, Wang Z. PARP inhibition restores erectile function by suppressing corporal smooth muscle apoptosis in diabetic rats. J Sex Med 2011;8:1072-82.
18. Obrosova IG, Drel VR, Pacher P, Ilnytska O, Wang ZQ, Stevens MJ, Yorek MA. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: The relation is revisited. Diabetes 2005;54:3435-41.
19. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjati K, Pacher P, Szabo C, Obrosova IG. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003;17:1514-6.
20. Chiu J, Farhangkhoee H, Xu BY, Chen S, George B, Chakrabarti S. PARP mediates structural alterations in diabetic cardiomyopathy. J Mol Cell Cardiol 2008;45:385-93.
21. Li WJ, Park K, Paick JS, Kim SW. Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. J Sex Med 2011;8:400-10.
22. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol 2005;25:915-22.
23. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: Role of the endothelium in erectile physiology and disease. J Androl 2003;24:S17-37.
24. Szabo C. Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol Res 2005;52:60-71.
25. Hans CP, Feng Y, Naura AS, Zerfaoui M, Rezk BM, Xia H, Kaye AD, Matrougui K, Lazartigues E, Boulares AH. Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: Effects on eNOS and oxidative stress. PLoS ONE 2009;4:e7430.
26. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-40.
27. Soriano FG, Virag L, Szabo C. Diabetic endothelial dysfunction: Role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 2001;79:437-48.
28. Csiszar A, Wang M, Lakatta EG, Ungvari Z. Inflammation and endothelial dysfunction during aging: Role of NF-kappaB. J Appl Physiol 2008;105:1333-41.
29. Hua HT, Albadawi H, Entabi F, Conrad M, Stoner MC, Meriam BT, Sroufe R, Houser S, Lamuraglia GM, Watkins MT. Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion. Arch Surg 2005;140:344-51.
30. Tapodi A, Debreceni B, Hanto K, Bognar Z, Wittmann I, Gallyas F, Jr, Varbiro G, Sumegi B. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J Biol Chem 2005;280:35767-75.
31. Mathews MT, Berk BC. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol 2008;28:711-7.
32. Hidalgo-Tamola J, Chitaley K. Review type 2 diabetes mellitus and erectile dysfunction. J Sex Med 2009;6:916-2633.
33. Szanto A, Hellebrand EE, Bognar Z, Tucsek Z, Szabo A, Gallyas F Jr, Sumegi B, Varbiro G. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol 2009;77:1348-57.
34. Hirata H, Kawamoto K, Kikuno N, Kawakami T, Kawakami K, Saini S, Yamamura S, Dahiya R. Restoring erectile function by antioxidant therapy in diabetic rats. J Urol 2009;182:2518-25.
35. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003;52:2353-62.
36. Fatehi-Hassanabad Z, Chan CB, Furman BL. Reactive oxygen species and endothelial function in diabetes. Eur J Pharmacol 2010;636:8-17.
37. Bivalacqua TJ, Usta MF, Kendirci M, Pradhan L, Alvarez X, Champion HC, Kadowitz PJ, Hellstrom WJ. Superoxide anion production in the rat penis impairs erectile function in diabetes: Influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2005;2:187-97.
38. Kendirci M, Zsengellér Z, Bivalacqua TJ, Gur S, Usta MF, Chen M, Szabó C, Hellstrom WJ. Poly(Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury. J Urol 2005;174:2054-9.
39. Ahn GJ, Chung HK, Lee CH, Kang KK, Ahn BO. Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl 2009;11:435-42.
40. De Young LX, Domes T, Lim K, Carson J, Brock GB. Endothelial rehabilitation: The impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol 2008;54:213-20.
41. Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 2007;7:515-23.
42. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, Schmalstieg FC, Komjati K, Mabley JG, Szabo C, Salzman AL, Traber DL. Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am J Physiol Lung Cell Mol Physiol 2003;285:L240-9.
43. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabo C. Diabetic endothelial dysfunction: The role of poly(ADP-ribose) polymerase activation. Nat Med 2001;7:108-13.
44. Lillie LE, Temple NJ, Florence LZ. Reference values for young normal Sprague-Dawley rats: Weight gain, hematology and clinical chemistry. Hum Exp Toxicol 1996;15:612-6.
45. Cellek S. Point of NO return for nitrergic nerves in diabetes: A new insight into diabetic complications. Curr Pharm Des 2004;10:3683-95.
46. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 2001;89:684-91.